Massachusetts Jail MOUD Study Finds Lower Overdose and Reincarceration

People with opioid use disorder who received medication while held in Massachusetts county jails were more likely to start treatment after release and less likely to overdose, be reincarcerated or die from any cause, according to a commentary published Oct. 23 in the Harm Reduction Journal that condenses seven years of research from a federally funded study hub.

The findings cover 6,383 incarcerated people with opioid use disorder who passed through seven jails between September 2019 and December 2020 and were released before July 2021, with six months of post-release follow-up. Of that group, 2,723 people, or 43 percent, received buprenorphine, methadone or naltrexone while in custody; 3,660, or 57 percent, did not.

The authors are Elizabeth A. Evans and colleagues from the Massachusetts Justice Community Opioid Innovation Network, known as MassJCOIN, one of more than 30 research hubs in the National Institute on Drug Abuse's Justice Community Opioid Innovation Network. Their commentary is less a single trial result than a ledger of what seven years of implementation science found when a state decided to make jail-based treatment a legal requirement.

What Chapter 208 actually did

Massachusetts became the first state to require county jails to offer every FDA-approved medication for opioid use disorder. Chapter 208 of the Acts of 2018 set up a four-year pilot at five jails, with two more joining voluntarily, and wrote three obligations into law: continue medication for people already receiving it before detention, start treatment before release for sentenced individuals when clinically appropriate, and arrange continuation in the community after release.

That mandate covered nearly half of the state's jails, a scale the researchers credit with changing what jail administrators believed was optional. The legal pressure did not come only from the Legislature. Lawsuits and settlements with the Department of Justice pushed the same direction, and the U.S. Attorney for Massachusetts opened a statewide compliance effort tied to protections under the Americans with Disabilities Act for people already prescribed medication before custody. By April 2022, every remaining correctional facility in the state offered all three medications.

The implementation findings are the useful part

For jurisdictions weighing a similar program, the commentary's detail on how the seven sites actually did it may matter more than the outcome numbers. Jails organized themselves in three different ways: contracting with a vendor to administer daily methadone while clinical staff handled buprenorphine and naltrexone; contracting a certified vendor to run an in-house opioid treatment program delivering all three; or obtaining their own certifications and licenses through a regulatory process the researchers describe as complex. Startup and operating costs varied widely depending on which route a county took, driven by dispensary construction, software and staffing.

Staffing absorbed more of the money than expected, because jails had to add correctional officers, medication clinicians and data staff at the same time they were renegotiating outside contracts. Interviews with 11 county sheriffs found that leadership was decisive: where institutional culture treated medication as contraband, sheriffs countered by educating staff, reallocating positions and building in-house programs to secure buy-in.

Diversion, the objection that most often stops jail programs before they start, turned out to be smaller than officials feared, particularly for buprenorphine. Staff and formerly incarcerated patients both reported diversion at lower rates than anticipated, and the availability of prescribed medication reduced the incentive, since some of the demand for diverted doses came from people trying to manage withdrawal themselves.

What patients said about the medication they got

The qualitative work surfaced a split that program designers rarely plan for. Some patients preferred long-acting injectable buprenorphine because it eliminated the taste of sublingual tablets, the daily trip to a dosing window and the daily reminder of their addiction, and because it also reduced opportunities for diversion. Others wanted the routine of daily dosing and distrusted needles or the idea of a depot they could not stop taking.

The study also documented a recommendation that goes beyond what most state laws require: offer medication to every incarcerated person with opioid use disorder at intake, including pretrial detainees who have not been sentenced and may be released within days. Under Chapter 208, new starts were generally timed to occur before release, leaving pretrial populations largely outside the program's reach.

Jail staff also reported a side effect that budget analysts seldom count. Because medication prevented withdrawal symptoms at intake, staff said it reduced acute mental health needs, suicide risk and behavioral instability in the first days of custody, cutting immediate pressure on both mental health and correctional personnel.

The limits of copying Massachusetts

The authors are explicit that the state's framework may not transfer cleanly. A legislative mandate covering half the jails in a state that already had a public health department able to co-run the research, a treatment financing system that pays for medication, and an active federal civil rights enforcement posture is not a template that a county commission can adopt on its own.

What does transfer is the arithmetic on continuity. The outcome differences in the Massachusetts data appear among people who were connected to community treatment quickly after release, which puts the burden on reentry planning, insurance activation and dosing appointments scheduled before the gate opens rather than after. Few U.S. jails currently offer these medications even when an incarcerated person asks for them, the authors note, contrary to current clinical guidance.

MassJCOIN's next phase is comparing the three medications against each other, documenting racial and ethnic disparities in who receives treatment in custody, and testing strategies for reaching incarcerated people the programs have so far missed. Those results will land in a policy environment where jail-based treatment is expanding in some states and stalled in others, often for reasons that have little to do with the evidence.